1 Min Read
* VERTEX RECEIVES EU APPROVAL FOR ORKAMBI® (LUMACAFTOR/IVACAFTOR) IN CHILDREN WITH CYSTIC FIBROSIS AGES 6-11 WITH TWO COPIES OF THE F508DEL MUTATION Source text for Eikon: Further company coverage:
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2018 Reuters. All Rights Reserved.